Coherus Oncology (CHRS) Accumulated Depreciation & Amortization: 2013-2025
Historic Accumulated Depreciation & Amortization for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $300,000.
- Coherus Oncology's Accumulated Depreciation & Amortization fell 25.00% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 40.91%. This contributed to the annual value of $1.8 million for FY2024, which is 43.75% down from last year.
- Latest data reveals that Coherus Oncology reported Accumulated Depreciation & Amortization of $300,000 as of Q3 2025, which was down 0.00% from $300,000 recorded in Q2 2025.
- Over the past 5 years, Coherus Oncology's Accumulated Depreciation & Amortization peaked at $19.0 million during Q3 2021, and registered a low of $300,000 during Q4 2024.
- In the last 3 years, Coherus Oncology's Accumulated Depreciation & Amortization had a median value of $500,000 in 2024 and averaged $545,455.
- As far as peak fluctuations go, Coherus Oncology's Accumulated Depreciation & Amortization grew by 19.99% in 2021, and later crashed by 95.59% in 2022.
- Quarterly analysis of 5 years shows Coherus Oncology's Accumulated Depreciation & Amortization stood at $16.8 million in 2021, then crashed by 94.06% to $1.0 million in 2022, then crashed by 30.00% to $700,000 in 2023, then slumped by 57.14% to $300,000 in 2024, then declined by 25.00% to $300,000 in 2025.
- Its Accumulated Depreciation & Amortization stands at $300,000 for Q3 2025, versus $300,000 for Q2 2025 and $400,000 for Q1 2025.